Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 1.00 |
| ▸ | TUBB | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050272 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13284579 | 0.91 | TUBB4A (0.84) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL682468 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL682203 | 0.90 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL676699 | 0.87 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL676906 | 0.87 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL676698 | 0.87 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12635400 | 0.87 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL676907 | 0.87 | TUBB4A (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29584050 | 0.87 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889705-B2 | Noscapine analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8841317-B2 | Noscapine and analogs and methods related thereto | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841317-B2 | Noscapine and analogs and methods related thereto | EMORY UNIVERSITY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8426398-B2 | Conjugates of noscapine and folic acid and their use in treating cancer | EMORY UNIVERSITY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130045203-A1 | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP | EMORY UNIVERSITY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | EMORY UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | EMORY UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2328578-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | Emory University (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100227878-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS | EMORY UNIVERSITY (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2010083104-A2 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | EMORY UNIVERSITY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010030582-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | EMORY UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010030582-A2 | NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION | EMORY UNIVERSITY (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2008109609-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS | EMORY UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227878-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS | CASP3, BCL3, TOP1 | TUBB4A 24/4885TUBB 9/4885TUBA3C 15/4885 |
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | TUBA1C, TUBB1, TUBB3 | TUBB4A 9/4885TUBB 4/4885TUBA3C 6/4885 |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | FOLR1, FOLR2, DHFR | TUBB4A 2968/4885TUBB 3211/4885TUBA3C 3044/4885 |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | NOS1, NOS2, TBCA | TUBB4A 13/4885TUBB 8/4885TUBA3C 21/4885 |
| US-20130045203-A1 | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP | APC, FAP, NTPCR | TUBB4A 2727/4885TUBB 3171/4885TUBA3C 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.